Loading company
Silence Therapeutics plc
SLN · Nasdaq · ·
Next earnings: November 5, 2026
$10.78-3.7%Sep 29 close
- 1M
- -19.7%
- 6M
- +116.5%
- 1Y
- +107.7%
- 5Y
- -51.0%
SLN · Nasdaq · ·
Next earnings: November 5, 2026
$10.78-3.7%Sep 29 close
Silence Therapeutics plc is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $224K | -100.00% |
| Profit | -$12.3M | -$27.4M | +55.15% |
| Profit per share | -$0.27 | -$0.57 | +52.63% |
| Free Cash Flow | $1.5M | -$21.8M | +106.95% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Releases land after the close or before the open, so the move is the session that follows.
Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD platform to create innovative siRNA therapies designed to precisely target and silence genes that cause disease. The Company is advancing a growing pipeline of siRNA product candidates targeting areas of high unmet need across rare and common diseases where treatments are limited or inadequate.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Silence Therapeutics plc’s Item 2.02 8-K filed August 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Silence Therapeutics plc has no earnings call transcript available.